Get the Stockscreener App
0.4866
23.99%
-0.1536
Pre-market:
.47
-0.0166
-3.41%
Genprex Inc stock is traded at $0.4866, with a volume of 1.61M.
It is down -23.99% in the last 24 hours and down -41.39% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
See More
Previous Close:
$0.6402
Open:
$0.61
24h Volume:
1.61M
Relative Volume:
2.64
Market Cap:
$5.32M
Revenue:
-
Net Income/Loss:
$-16.73M
P/E Ratio:
-0.0319
EPS:
-15.2598
Net Cash Flow:
$-14.29M
1W Performance:
-27.48%
1M Performance:
-41.39%
6M Performance:
-81.14%
1Y Performance:
-96.67%
1-Day Range:
$0.4821
$0.62
1-Week Range:
$0.4821
$0.696
52-Week Range:
$0.4821
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.4866 | 5.32M | 0 | -16.73M | -14.29M | -15.26 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GNPX Q1 2026 Earnings: Continued Losses as Clinical-Stage Biotech Focuses on Pipeline ProgressEarnings Miss Streak - newsline.com
Genprex, Inc. Files Form 8-K With Nasdaq Listing and Company Information – June 2026 - Minichart
Genprex faces potential delisting from Nasdaq after bid price rule violation - Investing.com UK
Genprex Faces Nasdaq Delisting Notice, Plans Compliance Steps - TipRanks
Genprex Received Notice of Delisting - TradingView
Genprex (NASDAQ: GNPX) confronts Nasdaq delisting risk after sub-$1 bid price - Stock Titan
Genprex Inc. (GNPX) Edges Higher Amid Low-Volume Consolidation Near Key Support LevelsMid Cap Momentum - newsline.com
GNPX Should I Buy - Intellectia AI
Genprex Inc. (GNPX) Edges Higher on Modest Volume, Faces Key Resistance at $0.68MA Cross Alert - newsline.com
Genprex Q1 2026 Earnings: Net Loss of $0.64 Per Share as Clinical-Stage Operations ContinueEarnings Surprise Report - newsline.com
Genprex (GNPX) files shelf registration to sell up to $250M in securities - Stock Titan
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
GNPX Q1 2026 Earnings: Net Loss Widens as Clinical-Stage Biotech Advances PipelineCash Flow Report - newsline.com
Genprex trades under $1 as ASCO results land - Bez Kabli
Genprex (GNPX) Edges Lower Toward $0.75 Support as Biotech Sentiment WaversETF NAV Deviation - thelegaladvocate.com
Genprex (GNPX) Slips 1.86% as Stock Tests Key Support at $0.74Supply Zone - newsline.com
Genprex (GNPX) Q1 2026 Earnings: Continued R&D Investment as Gene Therapy Pipeline ProgressesRevenue Surprise History - The Legal Advocate
Genprex reports biomarker data from lung cancer gene therapy study - Investing.com UK
Genprex, Inc. Announces Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - marketscreener.com
Genprex reports biomarker data from lung cancer gene therapy study By Investing.com - Investing.com Nigeria
Genprex Highlights Biomarker Data for Reqorsa Lung Cancer Therapy - TipRanks
Biomarker data link Trop-2 to PFS in Genprex (NASDAQ: GNPX) trials - Stock Titan
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - PR Newswire
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Reports Net Loss with No Revenue; Stock Moves Up $0.74Operating Income Trends - The Legal Advocate
Genprex Inc. (GNPX) Edges Higher Amid Biotech Sector Cautious ToneLow Vol Factor - Newser
Genprex (GNPX) Q1 2026 Earnings Stay the Course — EPS $-0.64Expert Stock Picks - Newser
Why Is Genprex, Inc. (GNPX) Stock Down Today? - Meyka
Genprex (GNPX) Showcases Promising Diabetes Gene Therapy Results - GuruFocus
Genprex, Inc. Files Form 8-K With SEC – Company Information and Filing Details for May 14, 2026 - Minichart
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex Presents Positive Preclinical Data on Novel Gene Therapy for Type 2 Diabetes at ASGCT 2026 Meeting - geneonline.com
Genprex collaborators present diabetes gene therapy data By Investing.com - Investing.com India
Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT - TradingView
Genprex collaborators present diabetes gene therapy data - Investing.com
[8-K] Genprex, Inc. Reports Material Event - Stock Titan
Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Genprex (NASDAQ: GNPX) raises cash through share sales amid going concern risk - Stock Titan
Genprex (GNPX) warrant holders report 249,788 shares, 2.69% stake - Stock Titan
GNPX Genprex quarterly results lack key metrics as clinical programs advance, investors await pipeline update.Guidance Upgrade Report - newsline.com
Number of shareholders of Genprex Inc – LSE:0A8I - TradingView
GNPX (Genprex) Q1 loss narrower than expected, beating estimates by 37.8% despite zero revenue and shares ticking higher.Miss Estimates - newser.com
Top 3 Health Care Stocks That Are Set To Fly In Q2 - Benzinga
What Genprex (GNPX) is doing that changes everything (Momentum Building) 2026-05-06Standard Deviation - newsline.com
GNPX Forecast, Price Target & Analyst Ratings | GENPREX INC (NASDAQ:GNPX) - ChartMill
MSN Money - MSN
Genprex, Inc. Files Form 8-K With SEC: Company Information, Nasdaq Listing, and Regulatory Details - Minichart
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatm - GuruFocus
Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel - TipRanks
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):